<DOC>
	<DOC>NCT00421096</DOC>
	<brief_summary>The scope of the trial is to assess the efficacy of the association gemcitabine-cisplatin + radiotherapy followed by an adjuvant chemotherapy</brief_summary>
	<brief_title>Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Age between 18 and 70 years old Cervical uterine cancer (epidermoid or adenocarcinoma, stage:from IB&gt; or = 4 cm to IV, according to FIGO classification) histologically proven Measurable lesions,clinically and by MRI assessed PSWHO &lt; or = 2 ou Karnofsky Index &gt;70 per cent Life expectancy &gt; 3 months Hematologic function: leukocytes &lt; or = 3 G/l, polynuclear neutrophil leukocytes &gt; or = 1.5 G/l, platelets &gt; or = 100 G/l, hemoglobin &gt; or = 10 g/dl Hepatic function: ASAT and ALAT &lt; 2.5 ULN Renal function: creatininemia &lt; 1.5 ULN, clearance &gt; 60 ml/min No prior chemotherapy or radiotherapy Contraception Written informed consent signed Stage IB &lt; 4 cm or IVB Other histology than epidermoid or adenocarcinoma Distant metastases, including susclavicular adenopathy Contraindication to MRI Pregnant or lactating woman Autoimmune disease Peripheric neuropathy, autograft or homograft, psychiatric disease Prior cancer (except cutaneous basocellular carcinoma and uterine cervical carcinoma in situ) Active infection Other clinical trial with an experimental drug Known positive serology (HIV, HbC, HbS)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>uterine cervical cancer</keyword>
</DOC>